Autoimmune hepatitis: Present knowledges;Epatite autoimmune: Conoscenze attuali

Minerva Medica

Volumn 95, Issue 1, 2004, Pages 1-9

  Durazzo, M ^a,b   Premoli, A ^a   Morello, E ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Dipartimento di Medicina Interna   (Italy)

Author keywords

Autoimmunity; Hepatitis therapy; Hepatitis, diagnosis

Indexed keywords

AMINOTRANSFERASE; AUTOANTIBODY; AZATHIOPRINE; CYCLOSPORIN A; HLA DR3 ANTIGEN; HLA DR4 ANTIGEN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STEROID; TACROLIMUS;

ANAMNESIS; AUTOIMMUNE HEPATITIS; AUTOIMMUNITY; CHOLESTATIC HEPATITIS; DRUG HYPERSENSITIVITY; GENETIC PREDISPOSITION; HISTOLOGY; HUMAN; HYPERGAMMAGLOBULINEMIA; IMMUNOSUPPRESSIVE TREATMENT; LIVER CIRRHOSIS; NAUSEA; PANCREATITIS; PATHOGENESIS; RASH; REVIEW; SCORING SYSTEM; SEROLOGY; SYMPTOMATOLOGY; VEIN OCCLUSION; VOMITING;

AUTOANTIBODIES; HEPATITIS C; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 2442691517     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Obermayer-Straub P, Strassburg CP, Manns MP. Autoimmune hepatitis. J Hepatol 2000;32 (1 Suppl.):181-97.
2. Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002;36:479-97.
3. Abdullah Al-Khalidi, Czaja AJ. Current concepts in the diagnosis, pathogenesis, and treatment of autoimmune hepatitis. Mayo Clin Proc 2001;76:1237-52.
4. Bittencourt PL, Goldberg AC, Cançado ELR, Porta G, Carrilho FJ, Farias AQ et al. Genetic heterogeneity in susceptibility to autoimmune hepatitis Types 1 and 2. Am J Gastroenterol 1999;94:1906-13.
5. Czaja AJ, Manns MP, McFarlane IG, Hoofnagle JH. Autoimmune hepatitis: the investigational and clinical challenges. Hepatology 2000;31:1194-200.
6. Goldstein NS, Bayati N, Silverman AL, Gordon SC. Minocycline as a cause of drug-induced autoimmune hepatitis. Report of four cases and comparison with autoimmune hepatitis. Am J Clin Pathol 2000;114: 591-8.
7. Mc Farlane IG. Pathogenesis of autoimmune hepatitis. Biomed Pharmacother 1999;53:255-63.
8. Czaja AJ, Manns MP. The validity and importance of subtypes in autoimmune hepatitis: a point of view. Am J Gastroenterol 1995;90:1206-11.
9. Durazzo M, Philipp T, Van Pelt FNAM, Lüttig B, Borghesio E, Michel G et al. Heterogeneity of liver-kidney microsomal autoantibodies in chronic hepatitis C and D virus infection. Gastroenterology 1995;108: 455-62.
10. Philipp T, Durazzo M, Trautwein C, Alex B, Straub P, Lamb JG et al. Recognition of uridine diphosphate glucuronosyl transferases by LKM-3 antibodies in chronic hepatitis D. Lancet 1994;344:578-81.
11. Duchini A, McHutchinson JG, Pockros PJ. LKM-positive autoimmune hepatitis in the western United States: a case series. Am J Gastroenterol 2000;95:3238-41.
12. Manns MP, Griffin KJ, Sullivan KF, Johnson EF. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest 1991;88:1370-8.
13. Wies I, Brunner S, Henninger J, Herkel J, Kanzler S, Meyer zum Büschenfelde KH et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 2000;355:1510-15.
14. Ballot E, Homberg JC, Johanet C. Antibodies to soluble liver antigen: an additional marker in type 1 auto-immune hepatitis. J Hepatol 2000;33:208-15.
15. Roozendaal C, de Jong MA, van den Berg AP, van Wijk RT, Limburg PC, Kallenberg CGM. Clinical significance of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune liver diseases. J Hepatol 2000;32:734-41.
16. Sobajima J, Ozaki S, Uesugi H, Osakada F, Inoue M, Fukuda Y et al. High mobility group (HMG) non-histone chromosomal proteins HMG1 and HMG2 are significant target antigens of perinuclear anti-neutrophil cytoplasmic antibodies in autoimmune hepatitis. Gut 1999;44:867-73.
17. Czaja AJ. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J Hepatol 1999;30: 394-401.
18. Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993;18:998-1005.
19. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL et al. International autoimmune hepatitis group report: rewiew of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929-38.
20. Czaja AJ. Drug therapy in the management of type 1 autoimmune hepatitis. Drugs 1999;57:49-66.
21. Fernandes NF, Redeker AG, Vierling JM, Villamil FG, Fong TL. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastroenterol 1999;94:241-8.
22. Debray D, Maggiore G, Girardet JP, Mallet E, Bernard O. Efficacy of cyclosporin A in children with type 2 autoimmune hepatitis. J Pediatr 1999;135:111-4.
23. Alvarez F, Ciocca M, Cañero-Velasco C, Ramonet M, de Davila MTG, Cuarterolo M. Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J Hepatol 1999;30:222-7.
24. Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 2000;33:371-5.
25. Dhawan A, Mieli-Vergani G. Mycophenolate mofetil - a new treatment for autoimmune hepatitis? J Hepatol 2000;33:480-1.
26. Reich DJ, Fiel I, Guarrera JV, Emre S, Guy SR, Schwartz ME et al. Liver transplantation for autoimmune hepatitis. Hepatology 2000;32:693-700.
27. Ratziu V, Samuel D, Sebagh M, Farges O, Saliba F, Ichai P et al. Long-term follow-up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease. J Hepatol 1999;30:131-41.
28. Narumi S, Hakamada K, Sasaki M, Freise CE, Stock PG, Roberts JP et al. Liver transplantation for autoimmune hepatitis: rejection and recurrence. Transpl Proc 1999;31:1955-56.
29. Milkiewicz P, Hubscher SG, Skiba G, Hathaway M, Elias E. Recurrence of autoimmune hepatitis after liver transplantation. Transplantation 1999;68:253-56.
30. Milkiewicz P, Gunson B, Saksena S, Hathaway M, Hubscher SG, Elias E. Increased incidence of chronic rejection in adult patients transplanted for autoimmune hepatitis: assessment of risk factors. Transplantation 2000;70:477-80.
31. Colle I, Hautekeete M. Remission of autoimmune hepatitis during pregnancy: a report of two cases. Liver 1999;19:55-7.
32. Yachha SK, Srivastava A, Chetri K, Saraswat VA, Krishnani N. Autoimmune liver disease in children. J Gastroenterol Hepatol 2001;16:674-7.
33. Ben-Ari Z, Czaja AJ. Autoimmune hepatitis and its variant syndromes. Gut 2001;49:589-94.
34. Durazzo M, Premoli A, Fagoonee S, Pellicano R. Overlap syndromes of autoimmune hepatitis: what is known so far? Dig Dis Sci 2003;48:423-30.
35. Floreani A, Baragiotta A, Guido M. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: a cause of resistance to ursodeoxycholic treatment. Dig Liver Dis 2003;35:128-9.
36. Strassburg CP, Manns MP. Autoimmune hepatitis versus viral hepatitis C. Liver 1995;15:225-32.
37. Lunel F, Abuaf N, Frangeul L, Grippon P, Perrin M, Le Coz Y et al. Liver/kidney microsome antibody type 1 and hepatitis C virus infection. Hepatology 1992;16: 630-6.
38. Manns MP, Rambusch EG. Autoimmunity and extrahepatic manifestations in hepatitis C virus infection. J Hepatol 1999;31 (Suppl. 1):39-42.
39. Michitaka K, Durazzo M, Tillmann HL, Walker D, Philipp T, Manns MP. Analysis of hepatitis C virus genome in patients with autoimmune hepatitis type 2. Gastroenterology 1994;106:1603-10.
40. Todros L, Saracco G, Durazzo M, Abate ML, Touscoz G, Scaglione L et al. Efficacy and safety of interferon alfa therapy in chronic hepatitis C with autoantibodies to liver-kidney microsomes. Hepatology 1995;22: 1374-78.
41. Durazzo M, Bresso F, Premoli A, Rabbione L. Sindromi varianti nelle epatopatie autoimmuni. Minerva Gastroenterol Dietol 2001;47:27-38.